

REMARKS

1. Applicants canceled, without prejudice, certain claims to facilitate prosecution. Applicants are grateful for the suggestions of the Examiner, which were adopted. Nucleotides of a variety of sizes, such as, nucleotides of sizes of less than 50 nucleotides are taught, for example, at page 54, last two lines and at page 55, first full paragraph; polynucleotides of at least 8 bases are taught in the first full paragraph of page 11; and nucleotides of at least 10, at least 15 and at least about 20 nucleotides are taught at page 33 of the instant specification. The specification defines such polynucleotides as being at least one nucleotide, page 27, 3rd full paragraph. Also, the instant specification teaches polypeptides of particular size, at page 38, fifth full paragraph, and at page 53, last full paragraph, for example. The polynucleotides that encode such polypeptides are three times the length of the peptides. Features of an ATP binding cassette protein of interest are provided at page 1, last full paragraph and on most of page 3 of the instant specification. Hence, no issue of new matter arises and entry of the amendments is requested respectfully.

2. Claims 1-5, 7-9, 12, 13, 16-25, 41-43, 47 and 51-63 were rejected under 35 U.S.C. §§ 101 and 112, first paragraph. The Examiner believed the claims are not supported by a specific and substantial asserted utility or a well established utility and thus, also are not enabled.

The two rejections are traversed for the following reasons.

Attached hereto is a copy of Akiyama et al., *J. Cli. Invest.* 115(7) 1777-1784, 2005. Akiyama et al. report additional examples of the disease association and the biological role of ABCA12, for example, replacement of a defective gene arising from mutation in ABCA12 domains restored overall function.

Clearly, the instant application, and hence the claims, provide a number of specific, substantial and credible uses of the nucleic acids of interest. The specification teaches thoroughly how to make and how to use a nucleic acid of interest. For example, probes identifying a mutation can be designed and used in a diagnostic assay for ichthyosis, as taught in the instant application. Therefore, utility exists and a prima facie case of non-enablement has not

been made. Accordingly, withdrawal of the § 101 and § 112, first paragraph rejections is requested respectfully.

3. On page 5 of the Office Action, the Examiner rejected claims 2-5, 41-43, 47 and 51 under § 112, first paragraph, stating that the specification does not enable polynucleotides that are 80%-98% identical to SEQ ID NOs: 1, 2, 3, or 4, polynucleotides that hybridize with a nucleotide sequence comprising at least 8 consecutive nucleotides of SEQ ID NOs: 1, 2, 3, or 4, or polynucleotides that hybridize with a nucleotide comprising SEQ ID NOs: 1, 2, 3, or 4.

The rejection is traversed for the following reasons.

The specification speaks at length about methods to produce and to use ABCA12 nucleotide derivatives resulting in fragments or sequences that are at least 80-98% identical to the sequences of SEQ ID NOs: 1, 2, 3, and 4.

Accordingly, claims 2-5, 41-43, 47 and 51 are enabled and in compliance with the statute. Withdrawal of the rejection is in order.

4. On page 6 of the Office Action, claims 2-5, 41-43, 47 and 51 were rejected under 35 U.S.C. § 112, first paragraph for an alleged want of written description. The Examiner maintained that the specification does not describe how to modify the nucleic acid of interest. The Examiner indicated that functional limitations may be beneficial.

The rejection is traversed for the following reasons.

The claimed invention relates to nucleic acids encoding polypeptides with ABCA12 function, as clearly stated in the instant application.

Thus, the written description requirement being satisfied, withdrawal of the rejection is in order.

5. On page 7 of the Office Action, claims 2, 5, 7, 9, 13, 16, 17, 47 and 51-63 were rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to comply with the written description requirement. The issue relates to new matter, and more specifically of the possible need to recite probes of particular size that are not explicitly recited in the specification.

The nucleic acids relate to expressing an ABCA12 function or identifying a nucleic acid expressing an ABCA12 function.

The specification teaches nucleotides of interest of at least 1000 bp in length, for example, or 50 bp or fewer, for example, 40 bp or fewer, 35 bp or fewer, 25 bp or fewer, and 20 bp or fewer bp, see page 11, third full paragraph. That paragraph teaches nucleotides comprising 1500 bp as well.

Further examples are provided in paragraph 1 hereinabove. Also, the instant specification teaches a variety of polypeptides. The application necessarily teaches polynucleotides that encode said polypeptides, as described, in part, in paragraph 1 above.

Thus, the specification clearly teaches nucleotides that comply with and are described by the claims. It is well settled that there need not be ipsissimis verbis concordance between the language in the specification and in the claims. All that is required is that the specification reasonably convey to the artisan what is being claimed, and the instant specification, in light of the state of the art of making and using probes, clearly teaches an extensive range of usable polynucleotides.

Thus, the rejection can be withdrawn.

6. Beginning at page 8 of the Office Action, the Examiner rejected claim 16 under 35 U.S.C. § 112, second paragraph.

Applicants thank the Examiner, his suggestion was adopted and hence, withdrawal of the rejection is requested respectfully.

7. On page 9 of the Office Action, the Examiner rejected claims 7, 13, 16 and 52-63 under 35 U.S.C. § 102(b) as allegedly being anticipated by the GenBank sequence of Ansorge et al.

The rejection is traversed for the following reasons.

The GenBank sequence of Ansorge et al. relates to a particular partial nucleic acid sequence. That GenBank sequence neither teaches nor suggests isolated nucleic acids larger or smaller than that specific sequence. For example, claims 7 and 13 recite an oligonucleotide of no

more than 50 bp. Ansorge et al. do not teach such an oligonucleotide. The same applies for consecutive nucleotides of shorter lengths.

Thus, there is no anticipation and the rejection can be removed.

CONCLUSION

Applicants respectfully submit that the claims are in condition for allowance. Reexamination, reconsideration, withdrawal of the objections and rejections, and early indication of allowance are requested respectfully. Should the Examiner believe that an interview would advance the prosecution of the instant application, Applicants invite her to contact the undersigned at the local exchange noted below.

The Commissioner is authorized to credit or debit Deposit Account No. 29180 if needed as relating to this paper to maintain pendency of the instant application. Finally, the undersigned avers having authority to act on behalf of applicants and the real parties in interest.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY


Dean H. Nakamura

Reg. No. 33,981

P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (202) 955-6851

Dated: 19 May 2006



Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer

Masashi Akiyama,¹ Yoriko Sugiyama-Nakagiri,¹ Kaori Sakai,¹ James R. McMillan,² Maki Goto,¹ Ken Arita,¹ Yukiko Tsuji-Abe,¹ Nobuko Tabata,³ Kentaro Matsuoka,⁴ Rikako Sasaki,⁵ Daisuke Sawamura,¹ and Hiroshi Shimizu¹

¹Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. ²Creative Research Initiative Sousei, Hokkaido University, Sapporo, Japan. ³Division of Dermatology, Japanese Red Cross Sendai Hospital, Yagiya, Tashiro, Sendai, Japan. ⁴Division of Pathology and ⁵Division of Dermatology, National Center for Child Health and Development, Okura, Setagaya, Tokyo, Japan.

Harlequin ichthyosis (HI) is a devastating skin disorder with an unknown underlying cause. Abnormal keratinocyte lamellar granules (LGs) are a hallmark of HI skin. ABCA12 is a member of the ATP-binding cassette transporter family, and members of the ABCA subfamily are known to have closely related functions as lipid transporters. ABCA3 is involved in lipid secretion via LGs from alveolar type II cells, and missense mutations in ABCA12 have been reported to cause lamellar ichthyosis type 2, a milder form of ichthyosis. Therefore, we hypothesized that HI might be caused by mutations that lead to serious ABCA12 defects. We identify 5 distinct ABCA12 mutations, either in a compound heterozygous or homozygous state, in patients from 4 HI families. All the mutations resulted in truncation or deletion of highly conserved regions of ABCA12. Immunoelectron microscopy revealed that ABCA12 localized to LGs in normal epidermal keratinocytes. We confirmed that ABCA12 defects cause congested lipid secretion in cultured HI keratinocytes and succeeded in obtaining the recovery of LG lipid secretion after corrective gene transfer of ABCA12. We concluded that ABCA12 works as an epidermal keratinocyte lipid transporter and that defective ABCA12 results in a loss of the skin lipid barrier, leading to HI. Our findings not only allow DNA-based early prenatal diagnosis but also suggest the possibility of gene therapy for HI.

Introduction

During the evolutionary process, when our ancestors left the safety of the aquatic environment, they developed a robust, protective mechanism or process in the skin that allowed adjustment to the new, dry environment; this is now known as keratinization. In humans, congenital defects involving skin keratinization cause a unique genodermatosis, ichthyosis (1, 2), which was named after the Greek word *ichthys*, meaning *fish*. Among the variety of types of ichthyosis, harlequin ichthyosis (HI) (Mendelian Inheritance of Man [MIM] 242500) is the most serious subtype (Figure 1); it is also the most severe congenital skin disorder of unknown etiology.

ABCA12 belongs to a large superfamily of ATP-binding cassette (ABC) transporters, which aid in the transport of various biomolecules across the cell membrane (3–5). The ABCA subfamily is thought to be important in lipid transport (6). ABCA12 is phylogenetically related to ABCA3, which is essential for alveolar surfactant lipid transport/secretion by lamellar granules (LGs) in type II alveolar lung cells. In skin, LGs are the most common secretory granules present in upper epidermal keratinocytes (7). Abnormal LGs are the most obvious characteristic findings in HI lesional epidermis. Furthermore, relatively minor missense mutations in ABCA12 have been reported to underlie type 2 lamellar ichthyosis (MIM 601277), a milder form of ichthyosis (8). Thus, we hypoth-

esized that ABCA12 mutations leading to serious ABCA12 protein defects might underlie HI.

In the present study, we demonstrate that ABCA12 works as an epidermal keratinocyte lipid transporter and that defective ABCA12 results in a loss of the skin lipid barrier, leading to HI. We have found 5 distinct truncation, deletion, or splice-site mutations in 4 independent HI families. These mutations were present on both alleles of our HI patients, either in compound heterozygous or homozygous state. We demonstrate that ABCA12 mRNA is expressed in normal human keratinocytes and that this expression is upregulated during keratinization. Our immunoelectron microscopic findings showed that ABCA12 protein localizes to LGs in the upper epidermal keratinocytes of human skin. Ultrastructural and immunofluorescent examination of human skin and cultured epidermal keratinocytes from HI patients who harbor ABCA12 mutations revealed defective lipid secretion of LG lipid contents. In addition, using ABCA12 corrective gene transfer in cultured HI keratinocytes, we have succeeded in restoring the normal ability of HI cells to secrete LG lipid.

Results

ABCA12 expression and localization in epidermal keratinocytes. To confirm the expression of ABCA12 mRNA in human epidermal keratinocytes, we performed semiquantitative RT-PCR assays and demonstrated strong expression of ABCA12 transcripts in cultured normal epidermal keratinocytes. To investigate the upregulation of ABCA12 during keratinization under high-Ca²⁺ conditions, we evaluated the ABCA12 transcript population against the GAPDH transcript using real-time RT-PCR. Calculation of the expres-


Nonstandard abbreviations used: ABC, ATP-binding cassette; CT, threshold cycle; HI, harlequin ichthyosis; LG, lamellar granule; MIM, Mendelian Inheritance of Man.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: *J. Clin. Invest.* 115:1777–1784 (2005). doi:10.1172/JCI24834.



research article


Figure 1

Clinical features of HI patients. (A) Patient 1 from family A harboring a homozygous mutation IVS23-2A→G in *ABCA12*. (B) Patient 2 from family B with compound heterozygous *ABCA12* mutations, IVS23-2A→G and 5848C→T (R1950X). (C) Patient 3 (family C) carrying compound heterozygous *ABCA12* mutations, 2021_2022del AA and 4158_4160delTAC (T1387del). (D) An affected fetus from family C aborted at 23 weeks' gestation showed no serious symptoms, although some abnormal keratinization was observed mainly on the cheeks and the perioral area.


sion ratios showed that *ABCA12* transcription was upregulated 4-fold after 1 week in high- Ca^{2+} culture. Furthermore, to confirm the expression of *ABCA12* protein in the epidermis, we raised a polyclonal anti-*ABCA12* antibody that recognizes an epitope near the C terminus of the *ABCA12* polypeptide (residues 2567–2580) and performed immunostaining for *ABCA12*. *ABCA12* was positive in the upper epidermal layers, mainly the granular layers, of normal human skin (Figure 2A); in contrast, there was an absence of immunolabeling in epidermal keratinocytes from HI patient 4 (Figure 2B), who harbors the homozygous truncation mutation

R434X (see below). This mutation resulted in truncation of the protein, leading to loss of the epitope for the anti-*ABCA12* antibody. These findings confirmed specificity of the anti-*ABCA12* antibody. In the epidermis of patient 1, who harbors a homozygous splice acceptor site mutation IVS23-2A→G (see below), weak *ABCA12* immunostaining was seen in the granular layer keratinocytes (Figure 2C). Immunoelectron microscopy revealed that *ABCA12* protein was restricted to the LGs in the cytoplasm of epidermal keratinocytes (Figure 2, D and E). *ABCA12*-positive LGs were abundant close to the cell membrane and were observed fusing with the cell membrane to secrete their lipid content to the extracellular space of the stratum corneum (Figure 2F). These results indicate that *ABCA12* is expressed in keratinocytes during keratinization and is likely to be involved in lipid transport into the extracellular space via LGs to form the stratum corneum lipid barrier (Figure 2G).

ABCA12 mutations in HI families. Full-length *ABCA12* protein comprises 2595 amino acids and includes 2 ABCs containing 3 characteristic, highly conserved motifs (Walker A, Walker B, and active transport signature). In addition, there are 2 transmembrane domains, each consisting of 6 hydrophobic membrane-spanning helices. Mutational analysis of the 53 exons, including the exon-intron boundaries of the entire *ABCA12* gene, revealed 5 novel, distinct mutations in both alleles, either in compound heterozygous

Figure 2

Localization and structure of *ABCA12* protein and the sites of HI mutations. (A) *ABCA12* protein (green) was localized in the cytoplasm of the upper epidermal keratinocytes (arrows) in healthy skin. (B) No *ABCA12* immunolabeling was seen in the epidermis of patient 4. (C) Weak *ABCA12* staining (arrows) was observed in the epidermis of patient 1. Asterisks indicate non-specific staining in the stratum corneum. Red, nuclear counterstain. Scale bar: 10 μm . (D–F) By immunoelectron microscopy, *ABCA12* protein (5 nm gold particles) was restricted to LGs (arrows) in the upper epidermal cell (D). Lamellar structures were apparent in some *ABCA12*-positive LGs (E). *ABCA12*-positive LGs (arrows) were observed close to the keratinocyte-cell membrane (white circles) and they fused with it to secrete their contents into the intercellular space (F). Scale bars: 0.2 μm . (G) Model of *ABCA12* function in the skin. *ABCA12* transports lipid into the LG, and *ABCA12*-positive LGs fuse with the cell membrane to secrete lipid into extracellular space to form the intercellular lipid layer. (H) Structure of *ABCA12* protein and the 5 mutation sites (red arrows) in HI families. Dark-blue area, cell membrane; bottom of dark-blue area, cytoplasmic surface.



or homozygous state, in all patients from 4 HI families (Figure 2H). The mutations in patients were homozygous in the 2 consanguineous families and compound heterozygous in the 2 nonconsanguineous families (Figure 3). The mutations were verified in the heterozygous parents. Each of the three mutations, 1300C→T (R434X), 2021_2022delAA, and 5848C→T (R1950X), resulted in truncation of a highly conserved region of the ABCA12 protein. The deletion mutation 4158_4160delTAC led to an in-frame deletion of a highly conserved threonine residue at codon 1387 (T1387del) within the first ATP-binding domain of the ABCA12 protein (Figure 4D). A splice acceptor site mutation, IVS23-2A→G, was verified by RT-PCR in mRNA from the patient's cultured keratinocytes (Figure 4, A-C). RT-PCR products from the patient showed 2 splice pattern variants different from the normal splicing variant in which 1 mutant transcript loses a 9-bp sequence from exon 24, which results in a 3-amino acid deletion (Y1099_K1101del). These 3 amino acids are located between the transmembrane domains and are highly conserved (Figure 4D). The other mutant transcript lost a 170-bp sequence from exon 24, which led to a frameshift. All of these mutations are thought to seriously affect either the function or specific critical structures of the ABCA12 protein.

Disturbed lipid secretion in epidermis of HI patients. Morphological observations revealed extraordinarily thick stratum corneum (Figure 5A) and abnormal LG secretion in keratinocytes of the epidermis of HI patients (Figure 5, C and E). Ultrastructurally, the cytoplasm in the stratum corneum was congested with abnormal lipid-containing droplets and vacuoles that resembled immature LG-like vesicles. In the keratinocyte cytoplasm of the granular layer, no normal LGs were apparent.

Immunofluorescent staining showed that glucosylceramide, a major lipid component of LG (7, 9) and an essential component of the epidermal permeability barrier (10), was diffusely distributed throughout the epidermis of HI patients (Figure 5G); this contrasts with the restricted, intense distribution in the stratum corneum of healthy skin (Figure 5H).

Abnormal lipid secretion in keratinocytes of HI patients and recovery of ABCA12 function by corrective gene transfer. Keratinocytes from patient 1, cultured under high-Ca²⁺ conditions (2.0 mM), expressed only a small amount of mutated ABCA12 protein (Figure 6). Culture of HI

keratinocytes under high-Ca²⁺ conditions (2.0 mM) induced a large number of cells to exhibit intense glucosylceramide staining around the nuclei, and this glucosylceramide failed to localize to the periphery of the keratinocyte cytoplasm (congested pattern) (Figure 6, A and C). Conversely, culture of healthy keratinocytes in high-Ca²⁺ conditions resulted in a large proportion of cells with diffuse glucosylceramide staining throughout the cytoplasm (widely-distributed pattern) (Figure 6, B and D). This difference was most pronounced after 1 week in culture (Figure 6, C and D). Electron microscopic observation of HI keratinocytes cultured for 1 week in high-Ca²⁺ conditions revealed that LGs formed, although proper secretion of their contents was not observed (Figure 6E). This finding suggests defects in LG lipid transport. Double immunostaining for ABCA12 protein





Figure 3

Families with HI and ABCA12 mutations. (A) Patient 1 from family A was a homozygote for the mutation IVS23-2A→G, and both his parents were heterozygous carriers. (B) Patient 2 from family B was a compound heterozygote for the mutations IVS23-2A→G and 5848C→T (R1950X). (C) Patient 3 from family C was a compound heterozygote for the mutations 2021_2022delAA and 4158_4160delTAC (T1387del). (D) Patient 4 from family D was a homozygote for the mutation 1300C→T (R434X), and her 2 parents were heterozygous carriers.



research article

**Figure 4**

Verification of splice-site mutation IVS23-2A→G and conservation of residues deleted by mutations IVS23-2A→G and 4158_4160delTAC (T1387del). (A) RT-PCR analysis of mRNA fragments around the exon 23–24 boundary indicated that keratinocytes from patient 1 (lane P) showed 2 different mutant transcripts, 674 bp and 513 bp, which were shorter than the control transcript (683 bp) from healthy human keratinocytes (lane C). Lane M, markers. (B) Sequencing of the mutant transcripts and the control transcript revealed that 9 nucleotides and 170 nucleotides were deleted in mutant transcripts. (C) A 9-nucleotide deletion resulted in the loss of 3 amino acids from the N terminal sequence of exon 24 (Y1099_K1101del), and the 170-nucleotide deletion led to a frameshift. (D) ABCA12 amino acid sequence alignment shows the level of conservation in diverse species of the amino acids, Y1099_K1101 and T1387 (red characters), which were deleted by mutations in HI families. Asterisks indicate ABC (abt-4).

and glucosylceramide clearly demonstrated that, before genetic correction of ABCA12, keratinocytes from patient 1 with a low expression of mutated ABCA12 protein showed a congested glucosylceramide distribution pattern (Figure 6, J–L). After genetic correction, however, the HI patient's keratinocytes, now expressing normal ABCA12, showed a normal, widely-distributed pattern of glucosylceramide staining (Figure 6, M–O). Corrective ABCA12 gene transfer into cultured HI keratinocytes resulted in a significant increase in number of cells exhibiting the widely-distributed pattern of glucosylceramide staining from $6.98\% \pm 3.33\%$ (control nontransfected patients' cells) to $16.70\% \pm 2.14\%$ (transfected patients' cells) (Student's *t* test, $P < 0.02$) (Figure 6P). These results clearly indicate that an ABCA12 deficiency leads to defective LG lipid transport into the intercellular space in HI patients, both in the epidermis and in cultured keratinocytes.


Discussion

An abnormal synthesis or metabolism of the LG lipid contents was previously suspected as being a possible pathogenetic mechanism underlying HI (11, 12). Here, we demonstrate that a severe ABCA12 deficiency causes defective lipid transport via LG in keratinizing epidermal cells, resulting in the HI phenotype.

The ABC transporter superfamily is one of the largest gene families, encoding a highly conserved group of proteins involved in energy-dependent active transport of a variety of substrates across membranes, including ions, amino acids, peptides, carbohydrates, and lipids (3–5, 13). ABC transporters have nucleotide-binding

folds located in the cytoplasm and utilize energy from ATP to transport substrates across the cell membrane (3–5). ABC genes are widely dispersed throughout the eukaryotic genome and are highly conserved between species (6). The ABCA subfamily, of which the ABCA12 gene is a member, comprises 12 full transporter proteins and 1 pseudogene (ABCA11). The ABCA subclass has received considerable attention (14) because mutations in these genes have been implicated in several human genetic diseases (15–19).

The ABCA1 protein is mutated in the following recessive disorders involving cholesterol and phospholipid transport: Tangier disease (MIM 205400), familial hypoalphalipoproteinemia (MIM 604091), and premature atherosclerosis, depending on the site of the mutations in the protein (17–19). The ABCA4 protein is mutated in Stargardt disease (MIM 248200) as well as in some forms of autosomal recessive retinitis pigmentosa (MIM 601718) and in the majority of cases of autosomal recessive cone-rod dystrophy (MIM 604116), depending on the mutation site or the combination of mutation types (15, 20). Heterozygous mutations in ABCA4 have also been implicated in some cases of macular degeneration (MIM 153800) (16, 20). In a relatively mild type of congenital ichthyosis (lamellar ichthyosis type 2), 5 ABCA12 mutations were reported in 9 families, and all 5 of these mutations were missense mutations that resulted in only 1 amino acid alteration (8). In the present series of HI patients, no ABCA12 missense mutations were identified, and most of the defects led to severe truncation of the ABCA12 peptide, affecting important nucleotide-binding fold domains and/or transmembrane domains. The other, nontrun-

**Figure 5**

Extremely thick stratum corneum and severe disruption of the secretion of LGs in the ABCA12-deficient skin of the present series of HI patients. (A) Strikingly thick stratum corneum (SC; double arrow) in the patient's skin. (B) Control epidermis showing normal, stratum corneum (arrow). (C) By electron microscopy, LG secretion was disturbed, and many abnormal immature (lacking proper lamellar structures) LGs (arrows) were observed in the keratinocytes. (D) In control skin, LGs (arrows) were distributed in a gradually increasing pattern toward the plasma membrane. (E) Abnormal HI LGs (arrows) were localized close to the cell membrane, but not secreted. (F) LGs were secreted into the extracellular space (arrows). (G) Patient's epidermis including stratum corneum (arrows) showed diffuse staining for glucosylceramide (green), a lipid component of LGs. (H) Glucosylceramide staining (green) was restricted and intense in the stratum corneum (arrows) of normal skin. Red, nuclear stain. Scale bars: 50 μm (A, B, G, H); 1 μm (C, D); 0.5 μm (E, F).


This might have some relevance to the fact that patient 1 survived infancy and is still alive.

ABCA1 and ABCA4 are suspected transmembrane transporters for intracellular cholesterol/phospholipids (23–25) and protonated *N*-retinylidenephosphatidylethanolamines (26), respectively. *ABCA2*, *ABCA3*, and *ABCA7* mRNA levels have been reported to be upregulated by sustained cholesterol influx mediated by modified low-density lipoprotein (27, 28), suggesting that ABCA transporters are involved in transmembrane transport of endogenous lipids (23–26). Keratinocyte LGs are known lipid-transporting granules, and LG contents are secreted into the intercellular space, forming an intercellular lipid layer between the granular layer cells and keratinized cells in the stratum corneum, which is essential for the proper barrier function of human skin. Our results indicate that ABCA12 functions in the transport of endogenous lipid across the keratinocyte cell membrane into the stratum corneum intercellular space via LGs. Immunohistological and immunoelectron microscopic observations have indicated that ABCA3 is involved in lipid secretion of pulmonary surfactant in human lung alveolar type II cells (29). ABCA3 and ABCA12 are very closely related in the ABCA subfamily phylogenetic tree (30). It is interesting that the functions of both ABCA3 and ABCA12 are involved in alveolar surfactant and stratum corneum lipid secretion, respectively. This suggests that these 2 transporter systems are evolutionary adaptations to aid the respiratory system and the integument in a dry environment, developed as vertebrates left the aquatic environment and began terrestrial lives. HI skin that harbors serious defects in ABCA12 highlights the important role(s) of epidermal lipid transport in adapting human skin to a terrestrial, dry environment.

HI is one of the most severe of all genodermatoses and has a very poor prognosis. Thus, parents' request for prenatal diagnosis is to be taken seriously and with care. However, to our knowledge, the causative gene was not identified until now. For the last 20 years, prenatal diagnoses have only been performed by electron microscopic observation of fetal skin biopsy at a late stage of pregnancy (19–23 weeks estimated gestational age) (31–33). In this report, we have identified the causative gene in HI, which now makes possible DNA-based prenatal diagnosis using chorionic villus or amniotic fluid sampling at an earlier stage of pregnancy, with a lower procedural risk and a reduced burden on prospective mothers, similar to that of screening for other severe genetic disorders, including keratinization disorders (34). Furthermore, we have performed correc-

cation mutations in HI were deletion mutations affecting highly conserved *ABCA12* sequences (Figure 4D). Thus, it is thought that only truncation or conserved region deletion mutations that seriously affect the function of the ABCA12 transporter protein lead to the HI phenotype. This is in contrast with diseases caused by mutations in other members of the ABCA family. Of *ABCA4* mutations causing Stargardt disease, 80% were missense, and many of these occurred in conserved domains of ABCA4 (21). Of *ABCA1* mutations resulting in Tangier disease, 60% were missense, located within the conserved domains of ABCA1 (22). In this context, *ABCA12* mutations underlying HI are unique in that these mutations are restricted to truncation or deletion mutations.

Patient 1 was homozygous for the splice acceptor site mutation IVS23-2A→G. This splice-site mutation was shown to lead to comparable amounts of 2 predicted transcripts, an inframe deletion of 3 amino acids, and a transcript with a 170-nucleotide deletion (frameshift) (Figure 4, A–C). Thus, it is still possible that patient 1 expresses some mutated ABCA12 protein. Indeed, expression of a small amount of ABCA12 protein, although mutated, was detected in the granular cells of the patient's epidermis and cultured keratinocytes by immunofluorescent staining (Figures 2C and 6J).



tive gene transfer in HI keratinocytes and succeeded in obtaining phenotypic rescue of a patient's cultured keratinocytes. These data provide significant clues that establish a strategic approach to HI gene therapy treatment. We believe that the genetic information presented in this study will be highly beneficial to our understanding of HI pathogenesis and in optimizing HI patient diagnosis, genetic counseling, care, and treatment.

Figure 6

Cultured HI keratinocytes carrying *ABCA12* mutations showed abnormal congestion of lipid, and this phenotype was recovered by corrective *ABCA12* gene transfer. (A–D) HI keratinocytes cultured in high Ca^{2+} conditions showed that glucosylceramide, a major component of LG lipid, was distributed densely around the nuclei (in a congested pattern) (green, FITC). Control normal human keratinocytes showed a widely distributed, diffuse glucosylceramide staining pattern. (E) Electron microscopic (EM) observation revealed, in cultured HI keratinocytes, that apparently amorphous, electron lucent LG-like structures (arrows) formed, but were not secreted. (F) Normal secretion of LG contents (arrow) in a control keratinocyte. (G–O) Before genetic correction, an HI patient cell showed weak *ABCA12* immunostaining (red, TRITC) and a congested pattern of glucosylceramide staining (green, FITC) (J–L). After genetic correction, an HI patient cell demonstrated stronger *ABCA12* labeling (red) and a normal distribution pattern of glucosylceramide (green) (M–O), similar to those of a normal human keratinocyte (G–I). (P) Corrective gene transfer resulted in a statistically significant increase in the number of cells with completely normal, widely distributed glucosylceramide patterns. * $P < 0.02$, Student's *t* test. Scale bars: 10 μm (A–D, G–O); 0.5 μm (E, F).

Methods

Patients and families. Four HI patients, patients 1–4, and 1 affected fetus, fetus 1 (4 males, 1 female), from 4 independent families, families A–D, showed a serious collapse in the keratinized skin barrier (Figure 1). Family A and family D were consanguineous (marriage of first cousins). All the patients showed severe hyperkeratosis at birth and presented with generalized, thick scales over their entire body surface with the presence of marked fissuring. Severe ectropion, eclabium, and malformed pinnae were apparent in all cases. Patient 2 from family B died 3 days after birth. Patient 3 from family C died 15 days after birth, and an affected fetus from family C was terminated at the parents' request after a positive prenatal diagnostic skin test (33). After written, informed consent was obtained, blood samples were collected from each participating family member, and skin biopsy or autopsy specimens were obtained from the patients and the affected fetus. The study was given appropriate ethical approval by the Ethics Committee at Hokkaido University Graduate School of Medicine.

Mutation screening. Mutation analysis was performed in patients, an affected fetus, and other family members in the 4 families, as far as DNA samples would allow. Briefly, genomic DNA isolated from peripheral blood was subjected to PCR amplification, followed by direct automated sequencing using an ABI PRISM 3100 genetic analyzer (Applied Biosystems). Oligonucleotide primers and PCR conditions used for amplification of exons 1–53 of *ABCA12* were originally derived from the report by Lefèvre et al. (8) and were partially modified for the present study. The entire coding region, including the exon/intron boundaries for both forward and reverse strands from all patients, family members, and controls, were sequenced. No mutations were found in 100 control alleles from the Japanese population.

Verification of the splice acceptor site mutation. In order to verify the splice acceptor site mutation IVS23-2A→G, RT-PCR amplification of mRNA spanning the exon 23–24 boundary was performed using mRNA samples from cultured HI keratinocytes (see below). After RT-PCR amplification, direct sequencing of the products was performed.

Establishment of HI keratinocyte cell culture. A skin sample from patient 1 was processed for primary keratinocyte culture, and cells were grown according to standard procedures in defined keratinocyte serum-free medium (Invitrogen Corp.). Cultures were grown for several passages in low- Ca^{2+} (0.09 mM) conditions and then switched to high- Ca^{2+} (2.0 mM) conditions.

RT-PCR of *ABCA12* mRNA. RT-PCR of *ABCA12* mRNA was performed with Superscript 2 (Invitrogen Corp.) following the manufacturer's



instructions. Specific primers for PCR amplification were as follows: forward 5'-GAATTGCAACTGGAAGGAAGTCCC-3' and reverse 5'-GAGT-CAGCTAGGATTAGACAGC-3'. These primers were used for amplification of a 683-bp fragment around exon 23-24 boundary of normal cDNA.

Real time-PCR. For quantitative analysis of *ABCA12* expression levels, total RNA extracted was subjected to real-time RT-PCR using the ABI PRISM 7000 sequence detection system (Applied Biosystems). Specific primers/probes for human *ABCA12*, TaqMan Gene Expression Assay (HS00292421; Applied Biosystems) were used. Differences between the mean CT values of *ABCA12* and those of *GAPDH* were calculated as $\Delta CT_{\text{sample}} = CT_{\text{ABCA12}} - CT_{\text{GAPDH}}$ and those of the ΔCT for the cultured keratinocytes in the low Ca^{2+} condition as ($\Delta CT_{\text{calibrator}} = CT_{\text{ABCA12}} - CT_{\text{GAPDH}}$). Final results, the sample-calibrator ratio, expressed as *n*-fold differences in *ABCA12* expression were determined by $2^{-(\Delta CT_{\text{sample}} - \Delta CT_{\text{calibrator}})}$.

Cloning of *ABCA12* and corrective gene transfer of HI keratinocytes. Using human keratinocyte cDNA as a template, overlapping clones of human *ABCA12* cDNA were amplified by PCR. A composite full-length cDNA was constructed, subjected to nucleotide sequencing, and subcloned into a pCMV-tag4B vector (Stratagene). The expression plasmid pCMV-tag4B-*ABCA12* was transfected into HI keratinocytes using Lipofectamine reagent (Invitrogen Corp.) according to the manufacturer's recommendation. As a control, pCMV-tag4B was transfected into the cells. The transfected cells and control cells from patient 1 were stained with anti-glucosylceramide antibody, and the number of keratinocytes showing the 3 distinct types of glucosylceramide distribution patterns — congested, intermediate, and widely distributed — were assessed and calculated by 1 observer after viewing under a confocal laser scanning microscope, the Olympus Fluoview, FV300 confocal microscope (Olympus).

Morphological observation. Skin biopsy samples or cultured keratinocytes were fixed in 2% glutaraldehyde solution, postfixed in 1% OsO_4 , dehydrated, and processed for conventional electron microscopic observation.

Antibodies. Polyclonal anti-*ABCA12* antibody was raised in rabbits using a 14-amino acid sequence synthetic peptide (residues 2567-2580) derived from the *ABCA12* sequence (NM 173076) as the immunogen.

The other primary antibody was mouse monoclonal anti-ceramide antibody (Alexis Biochemicals).

Immunofluorescent labeling. Immunofluorescent labeling was performed on frozen tissue sections and keratinocyte cultures as previously described (35). Fluorescent labeling was performed with FITC-conjugated secondary antibodies, followed by 10 $\mu\text{g}/\text{ml}$ propidium iodide (Sigma-Aldrich) to counterstain nuclei. For double labeling, fluorescent labeling was performed with a TRITC-conjugated secondary antibody for the anti-*ABCA12* antibody. The stained samples were observed under a confocal laser scanning microscope.

Postembedding immunogold electron microscopy. Normal human skin samples were obtained from skin surgical operations under fully informed consent and were processed for postembedding immunoelectron microscopy as previously described (36). Cryofixed, cryosubstituted samples were embedded in Lowicryl K11M resin (Electron Microscopy Sciences). Ultrathin sections were cut and incubated with anti-*ABCA12* antibody, a secondary linker antibody, and a 5-nm gold-conjugated antibody for immunogold labeling.

Acknowledgments

We thank members of the patients' families for their cooperation; Peter M. Elias for helpful discussion; Sadae Egawa, Haruhiko Sago, Judith Allanson, and Linlea Armstrong for their help; and Akari Nagasaki and Megumi Sato for their technical assistance. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan (Kiban B 16390312; to M. Akiyama).

Received for publication February 23, 2005, and accepted in revised form April 12, 2005.

Address correspondence to: Masashi Akiyama, Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W 7, Sapporo 060-8638, Japan. Phone: 81-11-716-1161; Fax: 81-11-706-7820; E-mail: akiyama@med.hokudai.ac.jp.

- Williams, M.L., and Elias, P.M. 1987. Genetically transmitted, generalized disorders of cornification; the ichthyoses. *Dermatol. Clin.* 5:155-178.
- Judge, M.R., McLean, W.H.I., and Munro, C.S. 2004. Disorders of keratinization. In *Rook's textbook of dermatology*. 7th edition. T. Burns, S. Breathnach, N. Cox, and C. Griffiths, editors. Blackwell Publishers, Oxford, United Kingdom. 34.1-34.111.
- Allikmets, R., Gerrard, B., Hutchinson, A., and Dean, M. 1996. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. *Hum. Mol. Genet.* 5:1649-1655.
- Dean, M., Rzhetsky, A., and Allikmets, R. 2001. The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res.* 11:1156-1166.
- Borst, P., and Elferink, R.O. 2002. Mammalian ABC transporters in health and disease. *Annu. Rev. Biochem.* 71:537-592.
- Peelman, F., et al. 2003. Characterization of the ABCA transporter subfamily: identification of prokaryotic and eukaryotic members, phylogeny and topology. *J. Mol. Biol.* 325:259-274.
- Ishida-Yamamoto, A., et al. 2004. Epidermal lamellar granules transport different cargoes as distinct aggregates. *J. Invest. Dermatol.* 122:1137-1144.
- Lefèvre, C., et al. 2003. Mutations in the transporter *ABCA12* are associated with lamellar ichthyosis type 2. *Hum. Mol. Genet.* 12:2369-2378.
- Vielhaber, G., et al. 2001. Localization of ceramide and glucosylceramide in human epidermis by immunogold electron microscopy. *J. Invest. Dermatol.* 117:1126-1136.
- Holleran, W.M., et al. 1993. Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function. *J. Clin. Invest.* 91:1656-1664.
- Dale, B.A., et al. 1990. Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. *J. Invest. Dermatol.* 94:6-18.
- Milner, M.E., O'Guin, W.M., Holbrook, K.A., and Dale, B.A. 1992. Abnormal lamellar granules in harlequin ichthyosis. *J. Invest. Dermatol.* 99:824-829.
- Higgins, C.F. 1992. ABC transporters: from microorganisms to man. *Annu. Rev. Cell Biol.* 8:67-113.
- Klein, I., Sarkadi, B., and Varadi, A. 1999. An inventory of the human ABC proteins. *Biochim. Biophys. Acta* 1461:237-262.
- Allikmets, R., et al. 1997. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. *Nat. Genet.* 15:236-246.
- Allikmets, R., et al. 1997. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science* 277:1805-1807.
- Brooks-Wilson, A., et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. *Nat. Genet.* 22:336-345.
- Rust, S., et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat. Genet.* 22:352-355.
- Oram, J.F. 2002. Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1. *Trends Mol. Med.* 8:168-173.
- Allikmets, R. 2000. Simple and complex ABCR: genetic predisposition to retinal disease. *Am. J. Hum. Genet.* 67:793-799.
- Lewis, R.A., et al. 1999. Genotype-phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease. *Am. J. Hum. Genet.* 64:422-434.
- Huang, W., et al. 2001. Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease. *Biochim. Biophys. Acta* 1537:71-78.
- Hayden, M.R., et al. 2000. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. *Curr. Opin. Lipidol.* 11:117-122.
- Orso, E., et al. 2000. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. *Nat. Genet.* 24:192-196.
- Schmitz, G., and Langmann, T. 2001. Structure, function and regulation of the ABC1 gene product. *Curr. Opin. Lipidol.* 12:129-140.
- Weng, J., et al. 1999. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. *Cell* 98:13-23.
- Klucken, J., et al. 2000. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. *Proc. Natl. Acad. Sci. U. S. A.* 97:817-822.
- Kaminski, W.E., et al. 2001. Complete coding sequence, promoter region, and genomic structure



research article

- of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages. *Biochem. Biophys. Res. Commun.* 281:249-258.
29. Yamano, G., et al. 2001. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. *FEBS Lett.* 508:221-225.
30. Annilo, T., et al. 2002. Identification and characterization of a novel ABCA subfamily member, ABCA12, located in the lamellar ichthyosis region on 2q34. *Cytogenet. Genome Res.* 98:169-176.
31. Blanchet-Bardon, C., et al. 1983. Prenatal diagnosis of harlequin fetus [letter]. *Lancet.* 1:132.
32. Akiyama, M., Kim, D.-K., Main, D.M., Otto, C.E., and Holbrook, K.A. 1994. Characteristic morphologic abnormality of harlequin ichthyosis detected in amniotic fluid cells. *J. Invest. Dermatol.* 102:210-213.
33. Akiyama, M., Suzumori, K., and Shimizu, H. 1999. Prenatal diagnosis of harlequin ichthyosis by the examinations of keratinized hair canals and amniotic fluid cells at 19 weeks' estimated gestational age. *Prenat. Diagn.* 19:167-171.
34. Tsuji-Abe, Y., et al. 2004. DNA-based prenatal exclusion of bullous congenital ichthyosiform erythroderma at the early stage, 10-11 weeks' of pregnancy in two consequent siblings. *J. Am. Acad. Dermatol.* 51:1008-1011.
35. Akiyama, M., et al. 1999. Periderm cells form cornified cell envelope in their regression process during human epidermal development. *J. Invest. Dermatol.* 112:903-909.
36. Shimizu, H., McDonald, J.N., Kennedy, A.R., and Eady, R.A.J. 1989. Demonstration of intra- and extra-cellular localization of bullous pemphigoid antigen using cryofixation and freeze substitution for postembedding immuno-electron microscopy. *Arch. Dermatol. Res.* 281:443-448.